NeuClone Makes Progress On Ustekinumab
Reports Positive Phase I Results; Phase III Trial To Begin In 2021
Australia’s NeuClone expects to be among the first biosimilar market entrants to challenge Stelara, with the firm’s NeuLara ustekinumab rival reporting positive Phase I data as the company prepares to move ahead with Phase III trials next year.
You may also be interested in...
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.